ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

Related Keywords

China ,Cambridge ,Cambridgeshire ,United Kingdom ,Hopkinton ,Massachusetts ,United States ,Chinese ,Jim Mourey ,Diana Zuckerman ,Layne Oliff ,Lou Gehrig ,Neil Thakur ,Sarah Nauser ,Terry Heiman Patterson ,Becky Mourey ,Relyvrio Heiman Patterson ,National Center ,Educational Media Group ,Drug Administration ,Veterans Administration ,Temple University ,Science Department ,Howard Hughes Medical Institute Science ,Health Research ,Amylyx Pharmaceutical ,United Statesdrugmakers ,Massachusetts Relyvrio ,Associated Press Health ,Howard Hughes Medical Institute ,Educational Media ,Pals ,Hnd ,